Thrombelastography Versus AntiFactor Xa Levels in the Assessment of Prophylactic-Dose Enoxaparin in Critically Ill Patients
- 1 June 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The Journal of Trauma and Acute Care Surgery
- Vol. 66 (6), 1509-1517
- https://doi.org/10.1097/ta.0b013e3181a51e33
Abstract
A standard dose of enoxaparin is frequently used for deep venous thrombosis (DVT) prophylaxis. Evidence suggests inconsistent bioavailability in intensive care unit (ICU) patients. Antifactor Xa activity (anti-Xa) has been used to monitor enoxaparin dosing but its accuracy and availability are problematic. Thrombelastography (TEG) is used to evaluate coagulation in diverse settings. The purpose of this study was to analyze whether TEG could be used to predict which enoxaparin-treated patients would develop DVT. Two hundred sixty-one simultaneous enoxaparin-active (active) and enoxaparin-neutralized (neutral) TEGs were performed in 61 surgical ICU patients over four consecutive days. Patient characteristics and anti-Xa were collected. DVT screening was per ICU protocol. Mean (+/-SEM) age was 54 (+/-2.3) years and Acute Physiology and Chronic Health Evaluation II score was 17 (+/-0.7). There were 30 trauma and 31 general surgery patients (69% men). The DVT rate was 28%. Time to clot formation (R) and percent lysis at 30 minutes were different between active versus neutralized blood (p < 0.001). R time was 1.5 minutes shorter in patients with DVT versus those without (p < 0.001) indicating hypercoagulability in DVT patients. Anti-Xa levels were similar in patients with (0.135 +/- 0.012) and without (0.135 +/- 0.007) DVT (p = 0.97). There were no differences in age, body mass index, injury severity score, Acute Physiology and Chronic Health Evaluation II score, or trauma status between DVT and non-DVT groups. TEG demonstrates differences between enoxaparin-neutralized and enoxaparin-active blood in ICU patients that may be used to guide dosing. TEG differentiates enoxaparin-treated patients who subsequently develop DVT while anti-Xa levels do not. TEG demonstrates an enoxaparin-related increase in fibrinolysis.Keywords
This publication has 27 references indexed in Scilit:
- Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patientsJournal of Critical Care, 2005
- Prevention of Venous ThromboembolismSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2004
- Prevention of Venous Thromboembolism in the ICUSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2003
- Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with CancerThe New England Journal of Medicine, 2003
- Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With CancerArchives of Internal Medicine, 2002
- Enoxaparin for thromboprophylaxis after major trauma: Potential cost implicationsCritical Care Medicine, 2001
- A Comparison of Low-Dose Heparin with Low-Molecular-Weight Heparin as Prophylaxis against Venous Thromboembolism after Major TraumaThe New England Journal of Medicine, 1996
- A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgeryThe American Journal of Surgery, 1995
- A Prospective Study of Venous Thromboembolism after Major TraumaThe New England Journal of Medicine, 1994
- Pulmonary Embolism in Major Trauma PatientsThe Journal of Trauma and Acute Care Surgery, 1990